FTRE Fortrea Holdings Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1965040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.4%
TTM net income YoY93.2%
TTM EPS YoY94.1%
Revenue 3-yr CAGR-2.7%
Net income 3-yr CAGR—
Margins
Gross margin20.0%
Operating margin0.5%
Net margin-2.6%
FCF margin6.3%
EBITDA margin3.4%
Returns
ROE-12.3%
ROA-2.5%
ROIC (approx.)0.7%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets80.6%
Debt / equity1.98x
Current ratio0.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.94x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.72B | $2.70B |
| Cost of revenue | $2.22B | $2.16B |
| Gross profit | $503.80M | $534.20M |
| SG&A expense | $456.40M | $560.70M |
| Operating income | -$872.60M | -$161.90M |
| Pretax income | -$983.00M | -$275.00M |
| Income tax | $3.20M | -$3.50M |
| Net income | -$986.20M | -$328.50M |
| EBITDA | -$794.60M | -$75.00M |
| EPS (basic) | -10.81 | -3.67 |
| EPS (diluted) | -10.81 | -3.67 |
| Weighted avg. shares (diluted) | — | 89.50M |
| Balance sheet | ||
| Cash & equivalents | $174.60M | $118.50M |
| Current assets | $897.20M | $948.20M |
| Goodwill | $960.00M | $1.71B |
| Intangibles | $622.00M | $655.70M |
| Total assets | $2.72B | $3.58B |
| Current liabilities | $913.30M | $949.50M |
| Short-term debt | $4.80M | $74.80M |
| Long-term debt | $1.05B | $1.05B |
| Total debt | $1.05B | $1.12B |
| Total liabilities | $2.15B | $2.22B |
| Shareholders' equity | $563.50M | $1.36B |
| Net debt | $878.20M | $1.01B |
| Shares outstanding | 93.10M | 89.70M |
| Cash flow statement | ||
| Operating cash flow | $113.50M | $262.80M |
| Capital expenditure | $25.20M | $25.50M |
| Free cash flow | $88.30M | $237.30M |
| Investing cash flow | $14.40M | $251.60M |
| Financing cash flow | -$76.30M | -$497.80M |
| Depreciation & amortization | $78.00M | $86.90M |
| Stock-based compensation | $74.40M | $58.40M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.